Home Tags #Dr. Reddy’s Laboratories Ltd

Tag: #Dr. Reddy’s Laboratories Ltd

Dr Reddy’s Labs announces launch of Bortezomib injection in US market

Hyderabad, July 27 : Dr. Reddy’s Laboratories Limited on Wednesday announced the launch of Bortezomib for Injection 3.5 mg, the generic equivalent of Velcade® (bortezomib) Injection, in the U.S. market approved by the U.S. Food and Drug Administration (USFDA). The Velcade Brand and generic had U.S. sales of approximately $1.2 billion MAT for the most recent 12 months ending in May 2022 according to IQVIA Health, Hyderabad based Pharma giant said in a release here. Dr. Reddy’s Bortezomib for Injection, is supplied in a 3.5 mg per 10 mL single-dose vial presentation for subcutaneous (SQ) or intravenous (IV) use.

Dr. Reddy’s and GRA announces Avigan Pivotal Studies Update Study for...

Kolkata, Jan 28 (UNI) Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy’s”) and Global Response Aid FZCO (GRA) today announced the termination of Avigan Trial Study conducted in Kuwait focused on moderate to severe COVID patients in a hospital setting.
- Advertisement -

MOST POPULAR